23rd Congress of the European Hematology Association (EHA)

Jun 15, 2018 at 5:30 PM CDT

Additional Information

Atara Biotherapeutics and its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present long-term clinical outcomes for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who failed first line treatment and were subsequently treated with tab-cel™ (tabelecleucel) in Phase 2 studies. The poster will be featured during the upcoming 23rd Congress of the European Hematology Association (EHA), which will be held in Stockholm, Sweden, June 14-17, 2018.


View press release and abstract


Details for the poster presentations are as follows:


Abstract PF401: Long Term Outcomes of Tabelecleucel (Allogeneic Third-Party EBV-Targeted Cytotoxic Tn Lymphocytes) for Rituximab-Refractory Post-Transplant EBV+ Lymphomas: A Single Center Experience


Session Title: Gene therapy, cellular immunotherapy and vaccination - Clinical


Presentation Date & Time: Friday, June 15; 5:30 p.m. to 7:00 p.m. CEST


Authors:Susan Prockop, Ekaterina Doubrovina, Amy Feng, Guenther Koehne, Parastoo Dahi, Esperanza Papadopoulos, Craig Sauter, Stephanie Suser, Willis Navarro, Akshay Sudhindra, Richard O'Reilly


Location: Poster area, Älvsjö building, Stockholm International Fairs and Congress Centre (Stockholmsmässan)